JP2018513862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513862A5 JP2018513862A5 JP2017554426A JP2017554426A JP2018513862A5 JP 2018513862 A5 JP2018513862 A5 JP 2018513862A5 JP 2017554426 A JP2017554426 A JP 2017554426A JP 2017554426 A JP2017554426 A JP 2017554426A JP 2018513862 A5 JP2018513862 A5 JP 2018513862A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- sjogren
- ylamine
- quinolin
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 4
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000034943 Primary Sjögren syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1506786.1 | 2015-04-21 | ||
| GBGB1506786.1A GB201506786D0 (en) | 2015-04-21 | 2015-04-21 | Therapeutic use |
| PCT/EP2016/058810 WO2016170014A1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513862A JP2018513862A (ja) | 2018-05-31 |
| JP2018513862A5 true JP2018513862A5 (https=) | 2019-04-25 |
| JP6721606B2 JP6721606B2 (ja) | 2020-07-15 |
Family
ID=53298950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554426A Active JP6721606B2 (ja) | 2015-04-21 | 2016-04-20 | シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10493074B2 (https=) |
| EP (1) | EP3285772B1 (https=) |
| JP (1) | JP6721606B2 (https=) |
| KR (1) | KR102627370B1 (https=) |
| CN (1) | CN107530344B (https=) |
| AR (1) | AR105552A1 (https=) |
| AU (1) | AU2016251236B2 (https=) |
| BR (1) | BR112017020591B8 (https=) |
| CA (1) | CA2981631C (https=) |
| CL (1) | CL2017002669A1 (https=) |
| CO (1) | CO2017010573A2 (https=) |
| CY (1) | CY1122572T1 (https=) |
| DK (1) | DK3285772T3 (https=) |
| EA (1) | EA032432B1 (https=) |
| ES (1) | ES2763335T3 (https=) |
| GB (1) | GB201506786D0 (https=) |
| HR (1) | HRP20192273T1 (https=) |
| HU (1) | HUE047162T2 (https=) |
| IL (1) | IL254766B (https=) |
| LT (1) | LT3285772T (https=) |
| MX (1) | MX2017013148A (https=) |
| MY (1) | MY192972A (https=) |
| PL (1) | PL3285772T3 (https=) |
| PT (1) | PT3285772T (https=) |
| SG (1) | SG11201707789YA (https=) |
| SI (1) | SI3285772T1 (https=) |
| WO (1) | WO2016170014A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2612862T1 (sl) * | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| EA017389B1 (ru) * | 2007-03-23 | 2012-12-28 | Амген Инк. | Гетероциклические соединения и их применение |
| PH12012500901A1 (en) * | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| ES2667173T3 (es) * | 2013-06-14 | 2018-05-09 | Gilead Calistoga Llc | Inhibidores de fosfatidilinositol 3-quinasa |
-
2015
- 2015-04-21 GB GBGB1506786.1A patent/GB201506786D0/en not_active Ceased
-
2016
- 2016-04-20 EA EA201792318A patent/EA032432B1/ru not_active IP Right Cessation
- 2016-04-20 PT PT167193564T patent/PT3285772T/pt unknown
- 2016-04-20 AU AU2016251236A patent/AU2016251236B2/en not_active Ceased
- 2016-04-20 PL PL16719356T patent/PL3285772T3/pl unknown
- 2016-04-20 AR ARP160101079A patent/AR105552A1/es not_active Application Discontinuation
- 2016-04-20 MX MX2017013148A patent/MX2017013148A/es active IP Right Grant
- 2016-04-20 WO PCT/EP2016/058810 patent/WO2016170014A1/en not_active Ceased
- 2016-04-20 KR KR1020177031275A patent/KR102627370B1/ko active Active
- 2016-04-20 HR HRP20192273TT patent/HRP20192273T1/hr unknown
- 2016-04-20 HU HUE16719356A patent/HUE047162T2/hu unknown
- 2016-04-20 DK DK16719356.4T patent/DK3285772T3/da active
- 2016-04-20 ES ES16719356T patent/ES2763335T3/es active Active
- 2016-04-20 SG SG11201707789YA patent/SG11201707789YA/en unknown
- 2016-04-20 LT LTEP16719356.4T patent/LT3285772T/lt unknown
- 2016-04-20 MY MYPI2017703917A patent/MY192972A/en unknown
- 2016-04-20 CA CA2981631A patent/CA2981631C/en active Active
- 2016-04-20 JP JP2017554426A patent/JP6721606B2/ja active Active
- 2016-04-20 SI SI201630565T patent/SI3285772T1/sl unknown
- 2016-04-20 BR BR112017020591A patent/BR112017020591B8/pt not_active IP Right Cessation
- 2016-04-20 CN CN201680022982.1A patent/CN107530344B/zh not_active Expired - Fee Related
- 2016-04-20 EP EP16719356.4A patent/EP3285772B1/en active Active
- 2016-04-20 US US15/565,866 patent/US10493074B2/en active Active
-
2017
- 2017-09-28 IL IL254766A patent/IL254766B/en active IP Right Grant
- 2017-10-17 CO CONC2017/0010573A patent/CO2017010573A2/es unknown
- 2017-10-20 CL CL2017002669A patent/CL2017002669A1/es unknown
-
2019
- 2019-12-23 CY CY20191101354T patent/CY1122572T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP2016163571A5 (https=) | ||
| JP2016512248A5 (https=) | ||
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2012532874A5 (https=) | ||
| RU2018144187A (ru) | Специфический аналог трифторэтилхинолина для применения при лечении apids | |
| JP2015534562A5 (https=) | ||
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| JP2017222722A5 (https=) | ||
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| JP2016147915A5 (https=) | ||
| JP2014198723A5 (https=) | ||
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EP4424374A3 (en) | Crystalline forms of tenofovir alafenamide | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| WO2015107536A3 (en) | Fixed dose combination comprising linagliptin and metformin hci | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| JP2018513862A5 (https=) | ||
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti |